“The Life Science business of Merck KGaA, Darmstadt, Germany is a proven leader in terms of the breadth and quality of products they offer for pharmaceutical development and ...

A microbioreactor is a way of “doing more with less” succinctly stated Wei-Xiang Sin, PhD, research scientist at SMART CAMP. As these tiny growth machines become even more sophisticated with machine ...

The healthcare pioneer shares insights on transformative diagnostics where precision medicine meets women’s health innovation ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Shares of Merck are sliding in early trading after ... due partly to a pause in shipments of one of its top-selling products to China Shares of Merck slid Tuesday after the drugmaker surprised ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 60 figures, this 133-page report Asia Pacific Bioprocess Technology Market 2023-2033 by Product (Instruments, ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...